CA2703946A1 - Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules - Google Patents

Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules Download PDF

Info

Publication number
CA2703946A1
CA2703946A1 CA2703946A CA2703946A CA2703946A1 CA 2703946 A1 CA2703946 A1 CA 2703946A1 CA 2703946 A CA2703946 A CA 2703946A CA 2703946 A CA2703946 A CA 2703946A CA 2703946 A1 CA2703946 A1 CA 2703946A1
Authority
CA
Canada
Prior art keywords
mammal
enhancing compound
diffusion enhancing
diffusion
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703946A
Other languages
English (en)
Inventor
John L. Gainer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diffusion Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2703946A1 publication Critical patent/CA2703946A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CA2703946A 2007-10-31 2008-10-31 Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules Abandoned CA2703946A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US109507P 2007-10-31 2007-10-31
US61/001,095 2007-10-31
PCT/US2008/012440 WO2009058399A1 (fr) 2007-10-31 2008-10-31 Nouvelle classe d'agents thérapeutiques qui améliorent la diffusion des petites molécules

Publications (1)

Publication Number Publication Date
CA2703946A1 true CA2703946A1 (fr) 2009-05-07

Family

ID=40583148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703946A Abandoned CA2703946A1 (fr) 2007-10-31 2008-10-31 Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules

Country Status (13)

Country Link
US (2) US8206751B2 (fr)
EP (1) EP2214714A4 (fr)
JP (2) JP2011502125A (fr)
KR (1) KR20100083820A (fr)
CN (1) CN101878040A (fr)
AU (1) AU2008319225B2 (fr)
BR (1) BRPI0818119A2 (fr)
CA (1) CA2703946A1 (fr)
EA (1) EA201070544A1 (fr)
IL (1) IL205417A0 (fr)
MX (1) MX2010004803A (fr)
WO (1) WO2009058399A1 (fr)
ZA (1) ZA201003475B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL373780A1 (en) * 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1853544A4 (fr) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc Transcarotenoides et leur synthese, leur preparation et leurs utilisations
US8283337B2 (en) * 2007-02-23 2012-10-09 Next21 K.K. Therapeutic or prophylactic agent for vasoconstriction
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US8206751B2 (en) 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
JP6076597B2 (ja) 2008-08-09 2017-02-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 化粧品としてのインドール化合物の使用
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
ES2654945T3 (es) * 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
CN102372623A (zh) * 2010-08-27 2012-03-14 江苏天晟药业有限公司 藏红花酸二铵盐
US20130323166A1 (en) * 2010-09-10 2013-12-05 William Beaumont Hospital Radiation Therapy for Treating Alzheimer's Disease
US20120171184A1 (en) * 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
CN103491981B (zh) 2010-12-31 2017-11-10 东塘实验室有限公司 含有环糊精的细胞水合组合物
CN102210869B (zh) * 2011-04-29 2012-07-25 山东弘立医学动物实验研究有限公司 四氢嘧啶及其衍生物在制备透皮吸收促进剂中的应用
CN102210868A (zh) * 2011-04-29 2011-10-12 济南环肽医药科技有限公司 四氢嘧啶及其衍生物在制备口服吸收促进剂中的应用
CN102210685B (zh) * 2011-04-29 2013-01-30 济南环肽医药科技有限公司 四氢嘧啶及其衍生物在制备预防和治疗化疗药物引发的口腔粘膜炎药物中的应用
CN102274238B (zh) * 2011-06-30 2012-10-03 山东弘立医学动物实验研究有限公司 一种治疗胰腺癌的药物组合物
CN102847161A (zh) * 2011-06-30 2013-01-02 山东弘立医学动物实验研究有限公司 四氢嘧啶及其衍生物在制备药物肺部收促进剂中的应用
CN102302498B (zh) * 2011-08-22 2012-10-03 济南环肽医药科技有限公司 一种治疗肾炎的药物
GB201120772D0 (en) * 2011-12-02 2012-01-11 Ip Science Ltd Cocoa-based food products
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
AU2014264228A1 (en) 2013-05-07 2015-11-12 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US20150345882A1 (en) * 2014-06-03 2015-12-03 Magpul Industries Corp Compact anti-tilt follower for an ammunition magazine
CN104069110A (zh) * 2014-07-14 2014-10-01 济南环肽医药科技有限公司 四氢嘧啶及其衍生物在制备血容量扩充药物中的应用
CN109152839A (zh) * 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
WO2018176098A1 (fr) 2017-03-31 2018-10-04 The Florey Institute Of Neuroscience And Mental Health Prophylaxie et traitement d'un dysfonctionnement et d'un déclin cognitifs
JP2017155046A (ja) * 2017-04-05 2017-09-07 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
EP3709975A4 (fr) 2017-11-16 2021-09-22 Aivita Biomedical, Inc. Utilisation de facteurs de signalisation liés à une membrane cellulaire
JP2019178154A (ja) * 2019-06-18 2019-10-17 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
CA3174816A1 (fr) 2020-04-06 2021-10-14 Lajos Szente Compositions favorisant l'hydratation cellulaire
KR102453320B1 (ko) 2022-04-29 2022-10-11 장세진 유속 증가 기능을 갖는 수류터빈 및 이를 활용한 수류발전 시스템
WO2024006901A1 (fr) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Utilisations de caroténoïdes trans bipolaires dans le traitement du cancer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948748A (en) 1960-08-09 Esters thereof
US2175843A (en) 1936-06-26 1939-10-10 Winthrop Chem Co Inc Polyene carboxylic acids and esters and manufacture thereof
US2175853A (en) * 1937-12-28 1939-10-10 Ross John Fisher Washing machine
US2948843A (en) * 1959-08-28 1960-08-09 Gen Electric Voltage limiter
CH468330A (de) 1966-01-28 1969-02-15 Hoffmann La Roche Verfahren zur Herstellung von isoprenoiden Verbindungen
US3489806A (en) 1967-01-19 1970-01-13 Hoffmann La Roche Isoprenoid compounds and a process for producing the same
CH522572A (de) 1969-10-31 1972-06-30 Hoffmann La Roche Verfahren zur Herstellung von Polyenverbindungen
US3853993A (en) 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
US3788468A (en) 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
DE2505869C3 (de) 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
US3965261A (en) 1975-04-29 1976-06-22 University Of Virginia Method for treating papillomas
US3975519A (en) 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4070460A (en) 1975-11-10 1978-01-24 University Of Virginia Patents Foundation Method for treating cerebral edema
US4009270A (en) 1975-11-21 1977-02-22 The University Of Virginia Method for treating spinal cord injury
US4038144A (en) 1976-04-19 1977-07-26 The University Of Virginia Method of increasing fermentation yields
US4046880A (en) 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
US4099270A (en) 1977-02-16 1978-07-11 Jabour Richard J Slip-on rubber gloves
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4176179A (en) 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
US4699664A (en) 1985-05-01 1987-10-13 Nestec S.A. Stabilized natural pigment complexes
US5032613A (en) * 1986-02-12 1991-07-16 W. Keith R. Watson Method and composition for treating arthritis
JPH0661211B2 (ja) 1986-08-29 1994-08-17 花王株式会社 パン用改質剤、パン生地及びパンの製造方法
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5472946A (en) * 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
FR2647343B1 (fr) 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
IT1233303B (it) 1989-06-07 1992-03-26 Azionaria Costruzioni Acma Spa Apparecchiatura per il convogliamento di prodotti
US5053240A (en) 1989-10-24 1991-10-01 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides
JPH04264020A (ja) 1991-02-18 1992-09-18 Yamanouchi Pharmaceut Co Ltd 安定な凍結乾燥製剤
US5107030A (en) 1991-03-04 1992-04-21 Loyola University Of Chicago Method of making 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof
JP3176716B2 (ja) 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
JP2977961B2 (ja) 1991-07-26 1999-11-15 株式会社資生堂 化粧料
JPH06248193A (ja) 1993-02-25 1994-09-06 Ensuiko Sugar Refining Co Ltd クロセチン含有着色料
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
JPH0723736A (ja) 1993-06-30 1995-01-27 Taishiyoo Technos:Kk カロチノイド色素の可溶化方法
JP2704356B2 (ja) 1994-02-08 1998-01-26 正和薬品株式会社 脳機能改善剤
JPH07291854A (ja) 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US6060511A (en) 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
JPH1129466A (ja) * 1997-07-09 1999-02-02 Lion Corp 水性皮膚外用剤
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6150561A (en) 1997-10-03 2000-11-21 Roche Vitamins Inc. Method of making carotenoids
JPH11209642A (ja) 1998-01-27 1999-08-03 Taito Kk アナトー色素製剤及びその製造方法
JP2000007570A (ja) * 1998-06-24 2000-01-11 Hayashibara Biochem Lab Inc 抗内分泌障害剤
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
JP2001051135A (ja) * 1999-08-06 2001-02-23 Hitachi Cable Ltd 光波長合分波器
GB2353934A (en) * 1999-09-09 2001-03-14 British Sugar Plc Nutritional compositions comprising trehalose for persons suffering from diabetes
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (fr) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition pharmaceutique pour utilisation ophthalmologique
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20030180282A1 (en) 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US7145025B2 (en) 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
DE10254809A1 (de) 2002-11-22 2004-06-03 Basf Ag Verfahren zur Herstellung von Carotinoiden
US20060233877A1 (en) * 2002-11-25 2006-10-19 Jallal Messadek Betaine compositions
US20040109920A1 (en) 2002-12-04 2004-06-10 Bioactives Llc Coated carotenoid cyclodextrin complexes
US20070166339A1 (en) * 2003-04-18 2007-07-19 Bioderm Research Skin Whitening Methods and Compositions Based on Zeolite - Active Oxygen Donor Complexes
JP2005053841A (ja) * 2003-08-05 2005-03-03 Kyouto Biomedical Science:Kk 皮膚外用剤
CN1842512A (zh) 2003-08-25 2006-10-04 扩散药品有限公司 双极性反式类胡萝卜素盐及其用途
US7446101B1 (en) 2003-12-12 2008-11-04 Bioactives, Llc Bioavailable carotenoid-cyclodextrin formulations for soft-gels and other encapsulation systems
ZA200700367B (en) * 2004-06-14 2008-07-30 Zoser B Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
JP4514114B2 (ja) 2004-06-18 2010-07-28 ヤマハ発動機株式会社 コイル可動形リニアモータおよび単軸ロボット
PL1811979T3 (pl) 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Mikrokapsułki zawierające metyloksantynę i kortykosteroid
US20060183185A1 (en) 2004-10-01 2006-08-17 Lockwood Samuel F Method for the synthesis of astaxanthin
EP1853544A4 (fr) * 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc Transcarotenoides et leur synthese, leur preparation et leurs utilisations
US20090176287A1 (en) 2005-02-24 2009-07-09 Regents Of The University Of Minnesota Producing carotenoids
EP1861109A2 (fr) 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoides, analogues de carotenoides ou derives de carotenoides permettant de traiter les troubles proliferatifs
DK1874932T3 (da) * 2005-04-26 2013-02-04 Boehringer Ingelheim Rcv Gmbh Produktion af rekombinante proteiner ved autoproteolytisk spaltning af et fusionsprotein
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
CN101242869B (zh) * 2005-09-02 2010-05-26 Iomai公司 经皮递送疫苗和透皮递送药物的装置及其应用
ITMI20052486A1 (it) 2005-12-23 2007-06-24 Italiana Sint Spa Procedimento di sintesi di intermedi per la preparazione di astaxantina
US20090169586A1 (en) 2006-03-24 2009-07-02 Ian Simon Tracton Stable packaged dosage form and process therefor
CN100571707C (zh) * 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
US8283337B2 (en) * 2007-02-23 2012-10-09 Next21 K.K. Therapeutic or prophylactic agent for vasoconstriction
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US8206751B2 (en) 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion

Also Published As

Publication number Publication date
JP2011502125A (ja) 2011-01-20
JP2016026156A (ja) 2016-02-12
MX2010004803A (es) 2010-09-09
EP2214714A1 (fr) 2010-08-11
KR20100083820A (ko) 2010-07-22
AU2008319225A1 (en) 2009-05-07
US20090110746A1 (en) 2009-04-30
ZA201003475B (en) 2011-10-26
AU2008319225B2 (en) 2016-09-29
US20130018014A1 (en) 2013-01-17
BRPI0818119A2 (pt) 2015-08-04
WO2009058399A1 (fr) 2009-05-07
IL205417A0 (en) 2010-12-30
EP2214714A4 (fr) 2011-01-12
EA201070544A1 (ru) 2010-12-30
CN101878040A (zh) 2010-11-03
US8206751B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
AU2008319225B2 (en) A new class of therapeutics that enhance small molecule diffusion
US10034944B2 (en) Wound healing using topical systems and methods
US9687504B2 (en) Brain and neural treatments comprising peptides and other compositions
Koshy et al. Anemia in children with chronic kidney disease
US20170281673A1 (en) Use of nitrite salts for the treatment of cardiovascular conditions
US9498535B2 (en) Wound healing using topical systems and methods
EP2309849B1 (fr) Procédé de traitement d&#39;une lésion cérébrale traumatique
Lippi et al. Biochemistry, physiology, and complications of blood doping: facts and speculation
Dubois et al. Lactated Ringer with 1% dextrose: an appropriate solution for peri‐operative fluid therapy in children
Ikuta et al. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization
Rodgers Recent approaches to the treatment of sickle cell anemia
Rodriguez et al. Sodium nitrite therapy attenuates the hypertensive effects of HBOC-201 via nitrite reduction
Cabrales et al. Microvascular Po2 during extreme hemodilution with hemoglobin site specifically PEGylated at Cys-93 (β) in hamster window chamber
US20080248012A1 (en) Erythrocyte Function Modifying Substance
Trissel et al. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use
EP1214933A1 (fr) Procede pour moduler le metabolisme des oxydes d&#39;azote, composition correspondante et ses variantes et procede pour agir sur l&#39;organisme d&#39;un patient necessitant une correction du metabolisme des oxydes d&#39;azote
Rajasab Efficacy of Acetaminophen and Magnesium Sulphate Versus Lignocaine in Reducing Pain While Administering Propofol Injection
Lim et al. Single-and repeat-dose toxicity of HM10760A, a long-acting erythropoietin, in rats and monkeys
Natarajan Liposomal formulations of alkyl nitrites and their efficacy in nitrosylation of blood
Zhang et al. Innovations in Breaking Barriers: Liposomes as Near-Perfect Drug Carriers in Ischemic Stroke Therapy
Kim et al. Stewart's physicochemical approach in neurosurgical patients with hyperchloremic metabolic acidosis during propofol anesthesia
US20100248376A1 (en) In-vitro method for testing bioequivalence of iron-sucrose formulation
Frise et al. Articles in PresS. J Appl Physiol (June 11, 2015). doi: 10.1152/japplphysiol. 00179.2015
MXPA97009695A (en) Liquid emulsion of fluorocarbon as vascular reserve of oxide nitr

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130919

FZDE Discontinued

Effective date: 20180205